Toxicity Can Be Reduced Using Cancer Drug With Better Staying Power

Tumor growth can be entirely stopped using a drug candidate that has been found in preclinical trials.

Tumor growth can be entirely stopped using a cancer drug that has been discovered in preclinical trials.

The drug delivers more cancer-busting power than many commonly used chemotherapy drugs and does so with fewer toxic side effects and more able to overcome resistance.

Cell Phone Radiation and Cancer - Unveiling the Link
Scared after hearing all the harmful effects of cell phone use? Read on to find more about what cell phone radiation actually does and how you can cut down on the exposure.

‘With optimized dosing, we might be able to wipe out these tumors entirely.’

Researchers from The University of Texas at Austin, The University of Texas MD Anderson Cancer Center and Austin-based biotech firm OncoTEX report their results this week in the journal Proceedings of the National Academy of Sciences.

"As a cancer researcher and cancer survivor, I’m excited by the fact that our compound shows promise for platinum-resistant ovarian cancer and platinum-resistant colon cancer, both of which have poor prognoses," said Jonathan Sessler, professor, and R.P. Doherty, Jr. - Welch Regents Chair in Chemistry at UT Austin and co-principal investigator on the project.

The drug candidate, called OxaliTEX, is made of two parts: a star-shaped molecule called texaphyrin that acts as a kind of delivery truck, and a modified version of a platinum drug that acts as a toxic package for cancer cells.

Colorectal Cancer Screening with Double-Contrast Barium Enema
Double-contrast barium enema is a radiological technique that can be used to screen individuals for colorectal cancer and is performed when colonoscopy is not possible.

Some of the most commonly used chemotherapy drugs -- such as cisplatin, carboplatin, and oxaliplatin -- can cause toxic side effects such as kidney damage. They also often lose effectiveness as cancerous cells develop resistance.

But the texaphyrin molecule is designed to be more easily absorbed by cancerous cells than healthy human cells, reducing the drug’s side effects. The new platinum drug has modifications that not only make it less toxic to healthy cells, further reducing side effects, but also that make it harder for cancerous cells to develop resistance.

Basal Cell Cancer-Risk Factors-Symptoms–Diagnosis–Treatment–Prognosis-Prevention
Basal cell cancer is a locally invading cancer. It often occurs on the face above a line joining the angle of the mouth and the ear lobe.

The drug was developed by four inventors: Sessler; Jonathan Arambula, now vice president for research at OncoTEX; Grégory Thibaud, a former UT Austin postdoctoral researcher, now a research associate at the Massachusetts Institute of Technology; and Zahid H. Siddik, a professor of pharmacology at MD Anderson.

The researchers compared the relative effectiveness of the new drug candidate OxaliTEX, and carboplatin, a platinum drug approved by the Food and Drug Administration commonly used to treat ovarian cancer, on mice that were carrying tumors. The mice that received carboplatin did not have a reduction in tumor growth.

Benefits of a Vegan Diet for Fighting Cancer
A vegan diet consisting of fruits, vegetables and other plant-based food sources has been shown to help prevent and fight many types of cancer.

Meanwhile, mice treated with OxaliTEX had 100% inhibition, meaning the tumors completely stopped growing. Two to three weeks after the drug treatment ended, tumors tended to begin growing again.

The researchers also compared relative toxic side effects in mice between the new drug candidate OxaliTEX and oxaliplatin, an FDA-approved platinum drug used to treat colorectal and other cancers. They found OxaliTEX had much lower toxicity.

"We created something that’s better tolerated than currently approved drugs," Arambula said. "That’s the big message." Next, the researchers plan to conduct more extensive toxicology studies and, assuming those go well, hope to start a Phase 1 human clinical trial within two years.

Source-Eurekalert